圣达生物
(603079)
| 流通市值：33.01亿 | | | 总市值：33.01亿 |
| 流通股本：1.71亿 | | | 总股本：1.71亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 165,761,629.44 | 237,212,440.53 | 271,800,830.11 | 323,722,320.84 |
| 应收票据及应收账款 | 160,715,841.98 | 149,496,761.96 | 128,767,574.62 | 118,145,823.72 |
| 其中：应收票据 | 2,796,823.75 | 393,300 | 2,879,273.3 | 1,215,026.25 |
| 应收账款 | 157,919,018.23 | 149,103,461.96 | 125,888,301.32 | 116,930,797.47 |
| 应收款项融资 | 1,215,583.94 | 1,584,994.56 | 2,241,592.11 | 1,112,435.57 |
| 预付款项 | 5,521,152.21 | 4,849,145.25 | 4,380,630 | 2,810,031.48 |
| 其他应收款合计 | 620,497.8 | 636,552.49 | 652,660.77 | 599,320.02 |
| 存货 | 204,973,773.88 | 233,344,732.39 | 238,910,554.47 | 228,482,255.95 |
| 一年内到期的非流动资产 | 29,286,375 | - | - | - |
| 其他流动资产 | 18,773,070.82 | 21,630,374.55 | 16,856,042.84 | 17,262,846.66 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 666,883,511.03 | 648,769,629.33 | 676,623,402.84 | 695,148,552.16 |
| 非流动资产: | | | | |
| 其他非流动金融资产 | 10,700,000 | 10,700,000 | 10,700,000 | 10,700,000 |
| 固定资产 | 425,297,692.72 | 409,500,502.46 | 422,415,686.84 | 427,038,182.01 |
| 在建工程 | 329,076,820.67 | 298,303,990.45 | 272,352,329.92 | 247,315,674.72 |
| 使用权资产 | 1,783,063.93 | 927,185.33 | 417,491.53 | 417,491.53 |
| 无形资产 | 227,228,253.4 | 228,385,959.74 | 230,100,779.81 | 231,815,599.9 |
| 商誉 | 10,909,393.98 | 10,909,393.98 | 10,909,393.98 | 10,909,393.98 |
| 长期待摊费用 | 9,472,385.17 | 10,878,330.13 | 11,976,316.77 | 8,670,991.1 |
| 递延所得税资产 | 476,154.01 | 331,131.05 | 759,751.4 | 889,251.68 |
| 其他非流动资产 | 57,833,662.04 | 75,427,057.64 | 118,935,596.13 | 86,280,420.8 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,072,777,425.92 | 1,045,363,550.78 | 1,078,567,346.38 | 1,024,037,005.72 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,739,660,936.95 | 1,694,133,180.11 | 1,755,190,749.22 | 1,719,185,557.88 |
| 流动负债: | | | | |
| 短期借款 | 30,025,416.67 | 30,025,416.67 | 111,975,777.76 | 93,993,881.93 |
| 应付票据及应付账款 | 162,932,641.48 | 155,627,753.39 | 159,871,166.25 | 144,354,689.27 |
| 其中：应付票据 | 79,538,783.31 | 84,028,768.42 | 84,859,499.11 | 76,769,707.21 |
| 应付账款 | 83,393,858.17 | 71,598,984.97 | 75,011,667.14 | 67,584,982.06 |
| 合同负债 | 9,859,182.35 | 2,776,931.62 | 6,504,964.58 | 2,923,295.97 |
| 应付职工薪酬 | 22,551,195.1 | 18,611,290.55 | 12,047,557.12 | 26,080,176.08 |
| 应交税费 | 12,136,023.49 | 9,861,113.25 | 4,170,437.6 | 10,999,973.87 |
| 其他应付款合计 | 1,622,497.17 | 1,605,481.73 | 14,105,087.86 | 16,368,389.02 |
| 一年内到期的非流动负债 | - | 472,184.69 | 304,323.57 | 447,323.57 |
| 其他流动负债 | 772,257.45 | 204,898.31 | 385,713.07 | 286,613.47 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 239,899,213.71 | 219,185,070.21 | 309,365,027.81 | 295,454,343.18 |
| 非流动负债: | | | | |
| 长期借款 | 210,000,000 | 194,000,000 | 173,000,000 | 144,000,000 |
| 租赁负债 | 1,793,105.25 | 556,029.6 | - | - |
| 预计负债 | 4,050,000 | 4,050,000 | - | - |
| 递延收益 | 6,745,198.69 | 7,103,050.86 | 6,106,071.02 | 5,464,423.38 |
| 递延所得税负债 | 3,047,545.31 | 3,044,122.35 | 4,540,110.41 | 4,276,770.45 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 225,635,849.25 | 208,753,202.81 | 183,646,181.43 | 153,741,193.83 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 465,535,062.96 | 427,938,273.02 | 493,011,209.24 | 449,195,537.01 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 171,188,958 | 171,188,958 | 171,188,958 | 171,188,958 |
| 资本公积 | 669,194,129.65 | 669,194,129.65 | 669,194,129.65 | 669,194,129.65 |
| 减:库存股 | 22,080,656.17 | 22,080,656.17 | 22,080,656.17 | 8,966,294.26 |
| 盈余公积 | 57,259,119.57 | 57,259,119.57 | 57,259,119.57 | 57,259,119.57 |
| 未分配利润 | 377,524,639.3 | 372,340,446.92 | 369,817,659.63 | 366,004,598.91 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,253,086,190.35 | 1,247,901,997.97 | 1,245,379,210.68 | 1,254,680,511.87 |
| 少数股东权益 | 21,039,683.64 | 18,292,909.12 | 16,800,329.3 | 15,309,509 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,274,125,873.99 | 1,266,194,907.09 | 1,262,179,539.98 | 1,269,990,020.87 |
| 负债和股东权益合计 | 1,739,660,936.95 | 1,694,133,180.11 | 1,755,190,749.22 | 1,719,185,557.88 |
| 公告日期 | 2024-10-26 | 2024-08-23 | 2024-04-20 | 2024-04-20 |
| 审计意见(境内) | | | | 标准无保留意见 |